Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3888518 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL305260 | 1.00 | — | — | |
| SCHEMBL10533402 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL4514650 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL7043940 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL305184 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL305058 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL153016 | 1.00 | — | — | |
| SCHEMBL22688944 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL31404556 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| US-20250034182-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-01-30 | — | — | US | disclosed |
| US-12116380-B2 | Phospholipid compounds and methods of making and using the same | GILEAD SCIENCES, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| EP-4387977-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-117858881-A | Phospholipid compounds and methods of making and using the same | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-3134458-B1 | PHOTOVOLTAIC CELL WITH BENZODITHIOPHENE-CONTAINING POLYMER | RAYNERGY TEK INC (TW) | 2023-11-01 | — | — | EP | disclosed |
| US-20230212199-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023023527-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| CN-109310660-A | Therapeutic combination and application thereof | 蜜纽康新西兰有限公司 | 2019-02-05 | — | — | CN | disclosed |
| EP-0170517-B1 | PROCESS FOR THE PRODUCTION OF 1,2-AMINO ALCOHOLS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-12-27 | — | — | EP | disclosed |
| EP-0170517-A2 | Process for the production of 1,2-amino alcohols | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1986-02-05 | — | — | EP | disclosed |
| EP-0053827-B1 | D-XYLOPYRANOSIDE SERIES COMPOUNDS AND THERAPEUTICAL COMPOSITIONS CONTAINING SAME | Seikagaku Kogyo Co. Ltd. (JP) | 1985-09-18 | — | — | EP | disclosed |
| US-4479901-A | Fluorination of carbanions with N-fluoro-N-alkylsulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-10-30 | — | — | US | disclosed |
| EP-0118676-A1 | D-Xylopyranoside series compounds and therapeutical compositions containing same | Seikagaku Kogyo Co. Ltd. (JP) | 1984-09-19 | — | — | EP | disclosed |
| EP-0117413-A1 | D-Xylopyranoside series compounds and therapeutical compositions containing same | Seikagaku Kogyo Co. Ltd. (JP) | 1984-09-05 | — | — | EP | disclosed |
| US-4454123-A | ANTICOAGULANTS, ANTITUMOR AGENTS | SEIKAGAKU KOGYO CO. LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| US-4428965-A | Tolerizing and desensitizing compounds, compositions and methods of treatment against dermatological conditions caused by allergens from plants and trees of the Anacardiaceae and Ginkgoaceae families | THE UNIVERSITY OF MISSISSIPPI (US) | 1984-01-31 | — | — | US | disclosed |
| EP-0053827-A2 | D-Xylopyranoside series compounds and therapeutical compositions containing same | Seikagaku Kogyo Co. Ltd. (JP) | 1982-06-16 | — | — | EP | disclosed |
| US-4065444-A | LOW TEMPERATURE IMPACT STRENGTH | UNIROYAL, INC. (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116380-B2 | Phospholipid compounds and methods of making and using the same | PHOSPHO1, SGMS1, SGMS2 | TSHR 4178/4885THRB 4523/4885DNM1 529/4885 |
| US-20230212199-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PHOSPHO1, SGMS1, SGMS2 | TSHR 4178/4885THRB 4523/4885DNM1 529/4885 |
| US-20250034182-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PHOSPHO1, SGMS1, SGMS2 | TSHR 4178/4885THRB 4523/4885DNM1 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.